BM213

Catalog No.P1215 Purity: 98%

BM213, a selective C5aR1 agonist with an EC50 of 59 nM, induces C5aR1-mediated calcium mobilization and pERK1/2 signaling but not β-arrestin recruitment. BM213 is much more stable in serum and displays no cytotoxicity on SHSY-5Y cells.

Amino-acid Sequence

CAS No.

Purity & Quality Control

Batch: P121501 Water] 100 mg/mL] false] ] ] false] ] ] false Purity: 98%

Chemical Information & Solubility

Storage (From the date of receipt)	3 years-20°C powder	Storage of Stock Solutions Aliquot the stock solutions to avoid repeated freeze-thaw cycles	1 year-80°Cin solvent
			1 month-20°Cin solvent

In vitro
Batch:

Water : 100 mg/mL

Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.

In vivo Formulation Calculator

Biological Activity

Description	BM213, a selective C5aR1 agonist with an EC50 of 59 nM, induces C5aR1-mediated calcium mobilization and pERK1/2 signaling but not β-arrestin recruitment. BM213 is much more stable in serum and displays no cytotoxicity on SHSY-5Y cells.

In vitro
In vitro	BM213 is a potent and stable peptide C5aR1 agonists that display no C5aR2 activity and over 1000-fold selectivity for C5aR1 over C3aR. BM213 induces C5aR1-mediated calcium mobilization and pERK1/2 signaling but not β-arrestin recruitment. BM213 is functionally similar to C5a in human macrophage cytokine release assays and in a murine in vivo neutrophil mobilization assay.^[1]
Cell Research	Cell lines	HMDMs, SHSY-5Y cells
	Concentrations	0.1-100 μM
	Incubation Time	0-6 h, 24 h
	Method	HMDMs are stimulated with LPS (10 ng/mL) alone or in the presence of BM213. The supernatant content of cytokines after 24 h stimulation is quantiﬁed using ELISA. For MTT cell survival assay, diﬀerentiated SH-SY5Y cells are treated with varying concentrations of BM213 following a 2.5 h incubation.

In Vivo
In vivo	BM213 shows antitumor activity in a mouse model of mammary carcinoma.^[1]
Animal Research	Animal Models	Mammary carcinoma model mice bearing with EMT-6 cells
	Dosages	1mg/kg
	Administration	IOCV

References
[1] Gorman DM, et al. J Med Chem. 2021 Nov 25;64(22):16598-16608.

References

[1] Gorman DM, et al. J Med Chem. 2021 Nov 25;64(22):16598-16608.

Product Information

Appearance:	White Powder
Peptide Content (by %N):	≥80%
Single Impurity (by HPLC):	≤1.0%
Assay (By Anhydrous, Acetic Acid-free):	95.0~105.0%
MS:	Consistent
Packing:	plastic vial(dedicated for peptide packing) or glass vial, quantity according to customer's detail requirement.
Storage (From the date of receipt):	3 years-20°C powder
Shipping:	Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)